The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma
暂无分享，去创建一个
R. Marcus | P. Zinzani | K. Ardeshna | S. Opat | Jie Jin | A. Tedeschi | P. Browett | P. McKay | X. Ke | D. Talaulikar | C. Thieblemont | J. Trotman | M. Coleman | E. Hawkes | F. Bijou | K. Linton | M. Co | C. Portell | S. Mapp | Shir-Jing Ho | Henry S H Chan | K. Zhou | M. Sobieraj-Teague | Mingyuan Sun | Jane E. Huang | P. Walker | Bei Hu | C. Tankersley | M. Cappellini | Xiaotong Li | Wenxiao Zhou | B. Hu | Henry Chan | Stephen Samuel Opat